NVCT
vs
S&P 500
NVCT
S&P 500
Over the past 12 months, NVCT has outperformed S&P 500, delivering a return of +25% compared to the S&P 500's +13% growth.
Stocks Performance
NVCT vs S&P 500
Performance Gap
NVCT vs S&P 500
Performance By Year
NVCT vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Nuvectis Pharma Inc
Glance View
Nuvectis Pharma, Inc. is a preclinical stage biopharmaceutical company. The company is headquartered in Fort Lee, New Jersey and currently employs 8 full-time employees. The company went IPO on 2022-02-04. The firm focuses on the development of precision medicines for the treatment of unmet medical needs in oncology. The company uses target selection, drug profiling, and clinical and regulatory execution to build a pipeline of anticancer targeted-therapy drugs. Its product pipeline consists of NXP800 and NXP900. The firm's lead product candidate, NXP800 is a clinical-stage, oral small-molecule inhibitor of the Heat Shock Factor 1 (HSF1) pathway. The company targets ovarian clear cell carcinoma (OCCC) and endometrioid ovarian cancer. NXP800 uses a synthetic lethality strategy to reduce the protective factors in the cell that are modified by overactivation of HSP1, with ARID1a gene defective cells being vulnerable. NXP900 is an oral small molecule designed to inhibit the roto-oncogene tyrosine-protein kinase (SRC) and YES1 kinases. The company is used for the treatment of SRC-associated solid tumors.
